Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer.

Stensgaard, Simone; Thomsen, Astrid; Helstrup, Sofie; Meldgaard, Peter; Sorensen, Boe S

Stensgaard, Simone; Thomsen, Astrid; Helstrup, Sofie; Meldgaard, Peter; Sorensen, Boe S.

Afiliación

Stensgaard S; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Thomsen A; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Helstrup S; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Meldgaard P; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Sorensen BS; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.

Transl Lung Cancer Res ; 12(5): 971-984, 2023 May 31.

Article en En | MEDLINE | ID: mdl-37323168

Palabras clave

Immunotherapy; biomarkers; circulating tumor DNA; liquid biopsy; lung cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transl Lung Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google